Skip to main content

Market Overview

UPDATE: JMP Securities Initiates Coverage on Lpath on Potential of iSONEP and ASONEP


In a report published Tuesday, JMP Securities analyst John L. Newman initiated coverage on Lpath (NASDAQ: LPTN) with a Market Outperform rating and $14.00 price target.

In the report, JMP Securities noted, “We are initiating coverage on Lpath with a Market Outperform rating and establishing a $14 price target based on a probability-adjusted Net Present Value calculation. Lpath is developing two lipid-targeting antibodies, iSONEP for eye disease, and ASONEP for kidney cancer, with iSONEP holding under-appreciated value, in our view.”

Lpath closed on Monday at $4.81.

Latest Ratings for LPTN

Apr 2014Canaccord GenuityInitiates Coverage OnBuy
Nov 2013McNicoll Lewis VlakInitiates Coverage OnBuy
Dec 2012Summer StreetInitiates Coverage OnBuy

View More Analyst Ratings for LPTN
View the Latest Analyst Ratings


Related Articles (LPTN)

View Comments and Join the Discussion!

Posted-In: JMP Securities John L. NewmanAnalyst Color Initiation Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at